Ultragenyx Pharmaceutical Inc [RARE] stock is trading at $35.34, up 1.20%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RARE shares have gain 13.78% over the last week, with a monthly amount drifted -10.85%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] stock has seen the most recent analyst activity on June 06, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $67 from $56. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on April 22, 2024, and set its price target to $77. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $72 on the stock. Evercore ISI upgraded its rating to a Outperform and raised its price target to $80 on June 06, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on April 26, 2023, and assigned it a price target of $114.
Ultragenyx Pharmaceutical Inc [RARE] stock has fluctuated between $29.59 and $60.37 over the past year. Currently, Wall Street analysts expect the stock to reach $89.75 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $35.34 at the most recent close of the market. An investor can expect a potential return of 153.96% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] reported sales of 560.23M for the trailing twelve months, which represents a growth of 29.42%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.96%, Pretax Profit Margin comes in at -1.01%, and Net Profit Margin reading is -1.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -1.94 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.70 points at the first support level, and at 34.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.76, and for the 2nd resistance point, it is at 36.18.
Ratios To Look Out For
For context, Ultragenyx Pharmaceutical Inc’s Current Ratio is 2.37. Further, the Quick Ratio stands at 2.24, while the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 5.92, the price to book ratio is 12.79.
Transactions by insiders
Recent insider trading involved Horn Howard, Chief Financial Officer, that happened on Mar 06 ’25 when 1785.0 shares were sold. CBO & EVP, Kassberg Thomas Richard completed a deal on Mar 03 ’25 to sell 6028.0 shares. Meanwhile, EVP and Chief Legal Officer Parschauer Karah Herdman sold 12846.0 shares on Mar 03 ’25.
